Literature DB >> 24217195

Plasma advanced glycation end products (AGEs), receptors for AGEs and their correlation with inflammatory markers in middle school-age children.

S Accacha1, W Rosenfeld, A Jacobson, L Michel, F J Schnurr, S Shelov, S Ten, C Boucher-Berry, D E Carey, P W Speiser, B Lowell, R Conroy, M Klein, I Fennoy, R Rapaport, M Rosenbaum.   

Abstract

AIM: Advanced glycation end products (AGEs) and/or their receptors (RAGE) are significantly positively correlated with adiposity, inflammation, dyslipidemia, and insulin resistance in adults. However, the relationships between AGEs, RAGE, and adiposity-related comorbidites in children have not been well studied.
METHODS: In a cross-sectional study of 88 children (age 11-15 years) from the New York area enrolled in the Reduce Obesity and Diabetes (ROAD) study, we examined the correlation of the AGE N(ε)-(carboxymethyl)lysine (CML), soluble RAGE (sRAGE), and endogenous secretory RAGE (esRAGE) with adiposity, inflammatory markers [interleukin-6 (IL-6), C-reactive protein, tumor necrosis factor-α], adiponectin, lipids, insulin sensitivity, and insulin secretory capacity.
RESULTS: Pediatric CML levels were ~20% below average adult levels. CML was significantly (p < 0.05) positively correlated with age and insulin sensitivity and negatively with adiposity, dyslipidemia and IL-6. sRAGE correlated positively with esRAGE and negatively with adiposity and IL-6. Both sRAGE and esRAGE correlated negatively with insulin secretory capacity.
CONCLUSION: Our findings suggest that unlike adults, CML is negatively associated with adiposity and adiposity-related comorbidity risk in children. As in adults, sRAGE and esRAGE were, to varying degrees, negatively correlated with body fatness and risk factors for adiposity-related comorbidities.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24217195     DOI: 10.1159/000354831

Source DB:  PubMed          Journal:  Horm Res Paediatr        ISSN: 1663-2818            Impact factor:   2.852


  10 in total

1.  A prospective study of soluble receptor for advanced glycation end-products and colorectal cancer risk in postmenopausal women.

Authors:  Liang Chen; Zhigang Duan; Lesley Tinker; Haleh Sangi-Haghpeykar; Howard Strickler; Gloria Y F Ho; Marc J Gunter; Thomas Rohan; Craig Logsdon; Donna L White; Kathryn Royse; Hashem B El-Serag; Li Jiao
Journal:  Cancer Epidemiol       Date:  2016-04-18       Impact factor: 2.984

2.  Advanced Glycation End Products: Building on the Concept of the "Common Soil" in Metabolic Disease.

Authors:  Henry H Ruiz; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Endocrinology       Date:  2020-01-01       Impact factor: 4.736

3.  Correlation among soluble receptors for advanced glycation end-products, soluble vascular adhesion protein-1/semicarbazide-sensitive amine oxidase (sVAP-1) and cardiometabolic risk markers in apparently healthy adolescents: a cross-sectional study.

Authors:  Radana Gurecká; Ivana Koborová; Melinda Csongová; Jozef Šebek; Katarína Šebeková
Journal:  Glycoconj J       Date:  2016-06-14       Impact factor: 2.916

Review 4.  Does AGE-RAGE Stress Play a Role in the Development of Coronary Artery Disease in Obesity?

Authors:  Kailash Prasad; Amal S Khan; Kalpana K Bhanumathy
Journal:  Int J Angiol       Date:  2022-02-12

Review 5.  Dietary Advanced Glycation End Products and Their Potential Role in Cardiometabolic Disease in Children.

Authors:  Anshu Gupta; Jaime Uribarri
Journal:  Horm Res Paediatr       Date:  2016-03-19       Impact factor: 2.852

6.  Association between Advanced Glycation End Products and Impaired Fasting Glucose: Results from the SALIA Study.

Authors:  Tom Teichert; Anne Hellwig; Annette Peßler; Michael Hellwig; Mohammad Vossoughi; Dorothea Sugiri; Andrea Vierkötter; Thomas Schulte; Juliane Freund; Michael Roden; Barbara Hoffmann; Tamara Schikowski; Christian Luckhaus; Ursula Krämer; Thomas Henle; Christian Herder
Journal:  PLoS One       Date:  2015-05-27       Impact factor: 3.240

7.  Soluble receptor for advanced glycation end products in critically ill patients and its associations with other clinical markers and 28-day mortality.

Authors:  Yanzi Cheng; Jiwen Zhong; Yang Xiang; Fan Zeng; Dehong Cai; Ling Zhao
Journal:  Clin Interv Aging       Date:  2014-11-19       Impact factor: 4.458

8.  Demographics and anthropometrics impact benefits of health intervention: data from the Reduce Obesity and Diabetes Project.

Authors:  L Ostrowski; P W Speiser; S Accacha; L Altshuler; I Fennoy; B Lowell; R Rapaport; W Rosenfeld; S P Shelov; S Ten; M Rosenbaum
Journal:  Obes Sci Pract       Date:  2019-01-16

9.  Association between Urinary Advanced Glycation End Products and Subclinical Inflammation in Children and Adolescents: Results from the Italian I.Family Cohort.

Authors:  Margherita Borriello; Fabio Lauria; Ivana Sirangelo; Krasimira Aleksandrova; Antje Hebestreit; Alfonso Siani; Paola Russo
Journal:  Nutrients       Date:  2022-10-05       Impact factor: 6.706

Review 10.  Dicarbonyl stress in clinical obesity.

Authors:  Jinit Masania; Malgorzata Malczewska-Malec; Urszula Razny; Joanna Goralska; Anna Zdzienicka; Beata Kiec-Wilk; Anna Gruca; Julita Stancel-Mozwillo; Aldona Dembinska-Kiec; Naila Rabbani; Paul J Thornalley
Journal:  Glycoconj J       Date:  2016-06-24       Impact factor: 2.916

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.